Clinical Trials Logo
  1. Home
  2. Herpes Genitalis
  3. NCT00158860

A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients. VALTREX® Tablet is a Trademark of the GlaxoSmithKline Group of Companies.

Herpes Genitalis Clinical Trial

Official title:
An International, Randomized, Double-Blind, Placebo-Controlled, Multicenter, 6-Month Study of the Efficacy and Safety of Valtrex 1g QD vs. Placebo for the Suppression of HSV-2 Genital Herpes in Newly Diagnosed Immunocompetent Patients

Clinical Trial Summary

Genital herpes (GH) is a commonly occurring sexually transmitted disease caused by herpes simplex virus (HSV). There are two types of HSV, type 1 (HSV-1) and type 2 (HSV-2); both can cause GH, although the latter is much more likely to produce frequent recurrences of GH lesions. Evidence suggests that there are advantages to using suppressive vs. episodic treatment, which include increased intervals between the pain and discomfort of genital herpes recurrences. Therefore, this study will collect safety and efficacy data on suppressive therapy with valaciclovir in subjects newly diagnosed with HSV-2 genital herpes.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00158860
Study type Interventional
Source GlaxoSmithKline
Contact
Status Completed
Phase Phase 4
Start date June 21, 2004
Completion date July 26, 2006
View Details
See also
  Status Clinical Trial Phase
Completed NCT02837575 - Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine Phase 2
Completed NCT02852876 - Study to Evaluate the Safety and Pharmacokinetics of Single Doses of ASP2151 in Healthy Male Subjects and the Effects of Food Phase 1
Completed NCT04664127 - Study of the Efficacy and Safety of Combined Treatment of Patients With Severe Herpes Simplex (HSV) Infection by Valacyclovir and Interferon Inducer Kagocel
Completed NCT00405821 - Acyclovir to Treat Patients Co-infected With HIV and Herpes Viruses in Uganda Phase 2
Completed NCT04165122 - Monoclonal Antibody Therapy Against Chronic Herpes Simplex Virus 2 Infection Phase 2
Completed NCT00158483 - Anti-Herpetic Treatment of Genital Ulcer : Effect on HIV & Herpes Shedding (ANRS 1212) Phase 2
Terminated NCT00079911 - A Clinical Research Study For The Suppression And Treatment Of Genital Herpes Infection In HIV-Infected Persons Phase 4
Active, not recruiting NCT04950712 - An Epidemiological Study to Assess Performance of Using Healthcare Tools to Understand Genital Herpes Simplex Virus-2 (HSV-2) in Patients ≥ 18 Years of Age in the United States and Europe.
Completed NCT00486200 - A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes Phase 2
Active, not recruiting NCT00005663 - A Study of Valacyclovir as Treatment for Genital Herpes Simplex Virus in HIV-Infected Patients Phase 3
Active, not recruiting NCT04073082 - Safety and Efficacy of Laser Therapy in Gynaecology
Terminated NCT00122525 - Effect of Male Circumcision on HIV Incidence (ANRS 1265) Phase 3
Completed NCT00158509 - Randomised Controlled Trial Assessing the Impact of Genital Herpes Suppressive Therapy on HIV Shedding Phase 2
Completed NCT00076232 - A Study of Acyclovir to Help Prevent HIV Infection in People With Genital Herpes Phase 3
Completed NCT00023582 - HIV and Genital Herpes Among High-Risk Men Who Have Sex With Men (MSM) in Lima, Peru N/A